A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

NCT05027945 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

NIH

Sponsor class

Conditions

Immunodeficiency
Hematopoietic Stem Cell Transplantation

Interventions

PROCEDURE: Allogeneic HSCT
DRUG: Busulfan test dose
DRUG: Mycophenolate mofetil (MMF)
DRUG: Tacrolimus
DRUG: Busulfan
RADIATION: Total Body Irradiation (TBI)
DRUG: Fludarabine
DRUG: Cyclophosphamide (CY)
DRUG: Post-Transplant Cyclophosphamide (PTCY)

Sponsor

National Cancer Institute (NCI)